ev3 prices IPO (Initial public offering)at $200m, plans Nasdaq listing
This article was originally published in Clinica
Executive Summary
ev3, the Plymouth, Minnesota developer of endovascular devices to treat cardiovascular, peripheral vascular and neurovascular diseases, has priced its planned initial public offering. The company intends to sell 11.77 million shares at $16-18 per share, and list on Nasdaq. Assuming a mid-point price of $17 per share, the company will raise $200m, or $182m net of expenses and underwriting discounts.